首页> Advances in therapy> Efficacy and Safety Analysis in Chinese Patients with Moderate-to-Severe Psoriasis from a Phase 3 Trial: Impact of Treatment Withdrawal and Retreatment of Ixekizumab.

Efficacy and Safety Analysis in Chinese Patients with Moderate-to-Severe Psoriasis from a Phase 3 Trial: Impact of Treatment Withdrawal and Retreatment of Ixekizumab.

导出 OA

翻译打印收藏纠错

第一作者： Xinghua,Gao

第一单位： Department of Dermatology, The First Hospital of China Medical University, Shenyang, 110001, China.

作者： Xinghua,Gao ^[1] ; Weili,Pan ^[2] ; Min,Zheng ^[3] ; Fuqiu,Li ^[4] ; Xiuqin,Dong ^[5] ; Dong,Lv ^[6] ; Zaipei,Guo ^[7] ; Jinnan,Li ^[8] ; Xuan,Wang ^[8] ; Songmei,Geng ^[9]

作者单位： Department of Dermatology, The First Hospital of China Medical University, Shenyang, 110001, China. ^[1] Department of Dermatology, Zhejiang Provincial People's Hospital, Hangzhou, 314408, Zhejiang, China. ^[2] Department of Dermatology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, 310003, Zhejiang, China. ^[3] Department of Dermatology, The Second Hospital of Jilin University, Changchun, 130041, Jilin, China. ^[4] Department of Dermatology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China. ^[5] Department of Dermatology, Yancheng First People's Hospital, Yancheng, Jiangsu Province, China. ^[6] Department of Dermatology, West China Hospital, Sichuan University, Chengdu, China. ^[7] Eli Lilly and Company, Shanghai, China. ^[8] Department of Dermatology, Northwest Hospital, The Second Hospital Affiliated to Xi'an Jiaotong University, 157 Xiwu Road, Xi'an, 710004, China. gengsongmei73@163.com. ^[9]

关键词 Chinese population Ixekizumab PASI Psoriasis sPGA